1. Home
  2. WKSP vs BIVI Comparison

WKSP vs BIVI Comparison

Compare WKSP & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Worksport Ltd.

WKSP

Worksport Ltd.

HOLD

Current Price

$0.82

Market Cap

13.2M

ML Signal

HOLD

Logo BioVie Inc.

BIVI

BioVie Inc.

HOLD

Current Price

$1.61

Market Cap

13.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WKSP
BIVI
Founded
2003
2013
Country
United States
United States
Employees
81
N/A
Industry
Auto Parts:O.E.M.
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.2M
13.3M
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
WKSP
BIVI
Price
$0.82
$1.61
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$9.25
N/A
AVG Volume (30 Days)
11.1M
218.2K
Earning Date
05-15-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$131.96
N/A
Revenue Next Year
$24.81
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.57
$1.06
52 Week High
$4.40
$9.09

Technical Indicators

Market Signals
Indicator
WKSP
BIVI
Relative Strength Index (RSI) 46.69 40.79
Support Level $0.63 $1.22
Resistance Level $1.36 $1.73
Average True Range (ATR) 0.16 0.26
MACD -0.02 -0.05
Stochastic Oscillator 11.22 8.85

Price Performance

Historical Comparison
WKSP
BIVI

About WKSP Worksport Ltd.

Worksport Ltd through its subsidiaries, designs, develops, manufactures, and owns the IP on a variety of tonneau covers, solar integrations, and NP (Non-Parasitic), Hydrogen-based true green energy solutions for the sustainable, clean energy, and automotive industries. The company's product includes soft vinyl tonneau covers and hard aluminum tonneau covers. It operates in two reporting segments for financial reporting purposes: Hard Tonneau Covers and Soft Tonneau Covers. Geographically, the company operates in Canada, United States and Other Countries.

About BIVI BioVie Inc.

BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.

Share on Social Networks: